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Abstract
Recent findings from the MRC-led South African Community Epidemiology Network on Drug Use (SACENDU) Project
(which collects data on treatment episodes from substance abuse treatment centres) point to a significant and
unprecedented increase in the proportion of clients reporting methamphetamine (MA) as their primary and/or secondary
drug of abuse at these specialist substance abuse treatment centres in the Western Cape.  For example, the proportion
of clients reporting methamphetamine-related problems has increased from 5% of the total treatment population at Cape
Town Drug Counselling Centre (the largest non-profit outpatient treatment centre in Cape Town) in 2003 to between 44%
and 48% of the treatment population in 2004.1
(SA Fam Pract 2006;48(2): 56-57)
Methamphetamine abuse,
psychosis and your patient
Pharmacodynamics
The rapidly growing popularity of MA
poses a new challenge to the health
sector as MA is associated with a range
of acute and chronic health and social
problems that need to be considered
during the course of treatment.  More
specifically, MA is a powerful psycho-
active stimulant which provides users
with a sense of euphoria and energy
through facilitating the release of large
amounts of the neurotransmitters
dopamine,  noradrenaline and adrena-
line from the nucleus accumbens.   In
the long-term, MA acts as a neurotoxin
with regular users showing a loss of
dopamine transporters in the caudate
and putamen, an early reduction in the
density of cortical white matter, reduced
glucose metabolism in the thalamus,
caudate and putamen, and increased
glucose metabolism in the parietal
cortex.2,3  These structural brain changes
are associated with acute and chronic
cognitive impairments (specifically recall
and recognition) and emotional deficits
(such as lasting depression, negative
symptoms of psychosis, and anxiety)




These emotional and cognitive deficits
have important implications for the
treatment and management of MA-using
patients.  The key role of most Family
Physicians would be to refer patients to
a suitable substance abuse treatment
provider.  Suitable substance abuse
treatment providers would be registered
with the National Department of Social
Development, would provide a
structured programme that is based on
evidence-based models of treatment
(such as the Matrix model, Cognitive
Behavioural models, Twelve-step
models, and Motivational Enhancement
Models), and would have a good mix
of professional  and paraprofessional
staff.  In addition, with methamphe-
tamine-abusing patients, the Family
Physician needs to assess the patient’s
level of cognitive functioning (especially
any deficits relating to learning and
memory) to determine whether the
patient can travel safely to outpatient
treatment services or whether they
would be better suited to a supervised
inpatient or residential treatment
programme. As part of an effective
referral strategy, the Family Physician
should also make sure that the treatment
programme is aware that methampheta-
mine-abusing patients may have
cognit ive deficits and that the
programme is able to compensate for
difficulties in learning and memory
through using cognitive strategies such
as breaking complex tasks into simple
steps; providing patients with a clear
and wel l -s t ructured t reatment
programme; and using repetition,
behaviour rehearsal and pictures to
reinforce and enhance learning and skill
acquisition during treatment. 3-4   In
addition, the Family Physician should
also ensure, prior to referring patients
to a substance abuse treatment
programme, that the programme is able
to treat patients with co-occurring mental
health problems.  For example, people
with MA-related problems may
experience lasting depression and
anxiety that should be managed as part
of an effective treatment strategy.  The
failure to manage these emotional
deficits may result in the patient self-
medicating with MA in order to alleviate
emotional discomfort.3,4,5
MA-induced psychosis
Acute and/or chronic MA-induced
psychosis also poses a challenge to
the health sector as MA users in other
parts of the world often present at
emergency rooms, psychiatric and
general hospitals, and at general




• Well-formed persecutory delusions.
• Labile and/or inappropriate affect
that may include uncontrollable
outbursts of rage and violent
behaviour.
• Negative symptoms of psychosis.
It is highly probable that MA users in
South Africa will also seek assistance
from primary and emergency health
care services, thus necessitating the
Merck South Africa's social responsibility programme
focuses on the upliftment of disadvantaged communities
through the improvement of rural healthcare. One such
programme is the Alexandra Health Centre and University
Clinic and recently made their annual contribution of R40
000.
 
For almost 20 years, Merck SA has supported the Centre;
at least one of Merck South Africa's employees was born
at Alexandra Health Centre and a number of the employees'
children were delivered there. Deon Vos, CEO of Merck,
says ,"Escalating running expenses, the replacement of
equipment and the salaries of experienced, dedicated staff
all contribute towards the costs. Merck contributes to the
Clinic in the hope that our donations will assist in keeping
its doors open to continue providing the outstanding service
for which it has become renowned."
 
The Alexandra Health Centre is a medical facility in the
heart of Alexandra Township but not everyone who comes
to the clinic is in need of medical attention. Many visit to
simply sit in the gardens, which are a rarity in the township.
While Alexandra Health Centre does provide basic
healthcare to the community, it is primarily a maternity
facility. However, as with many clinics like this one, funding
from the Government is minimal and they are reliant on
contr ibut ions f rom business and the publ ic.
 
Vos concludes, "We are so proud of our association with
the Alexandra Health Centre and want to say a big
'congratulations' to the Centre and staff for the difference
they continually make in their community."
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training of service providers in the
diagnosis and management of MA-
induced psychosis.  Mental health and
substance abuse treatment service
providers also need to be trained to
distinguish between MA-induced
psychosis, other forms of toxic
psychosis, and non-toxic psychosis as
these require different long-term
management strategies.
At present, the most commonly
accepted regime for stabilizing patients
with acute MA-induced psychosis is the
following: 5 mg Haloperidol IM, 1 mg
Clonazepam IM, 1 mg Benztropine IM;
placing the patient in a quiet dimly lit
room or, if this is not practical, a room
with low levels of noise and sensory
stimulation; and if necessary placing
the patient in restraints. 5 Residual
paranoia and agitation among patients
should be managed through providing
these patients with a safe, reassuring
treatment environment and conducting
brief and directive behavioural
interventions that recommend sleep,
nutrition and low stimulation.
A further challenge to primary and
emergency health care service
providers lies in the detection and
management of MA withdrawal and
overdose. Health care professionals
need to be trained to recognize and
distinguish MA withdrawal from other
withdrawal syndromes.  They also need
to be trained to manage the symptoms









Given these challenges that MA poses
to health professionals, this short report
makes a strong case for the role of the
health sector in the provision of
evidence-based treatment for MA abuse
and MA-related health problems. In
order to fulfill this role, it is important
that the health sector (such as the
Department of Health, Medical Schools
and experienced and competent
service providers) provides health care
professionals with evidence-based
information and training related to the
diagnosis and management of MA
misuse and related health problems. 
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